The treatment of advanced renal cell carcinoma has posed a challenge for decades, in part because of common themes related to intrinsic resistance to cytotoxic chemotherapy and the obscure biology of these cancer types. Forward movement in the treatment of the renal cell carcinomas thus can be approached in 2 ways: by splitting the tumor types along histologic and molecular features, in the hopes of coupling highly precision-focused therapy on a subset of patients who have disease with the most potential for benefit; or by lumping the various biologies and histologies together, to include the rarer renal cell carcinoma types with the more common types. The former strategy satisfies the desire for customized precision in treatment delivery, whereas the latter strategy allows clinicians to offer a wider therapeutic menu in a set of diseases we are continuing to learn about on a physiologic and molecular level. 
INTRODUCTION
The study of biology has been propelled forward over the years by field-shifting technologic advances that bring scientific details into greater resolution. These advances have revolutionized multiple fields, including cancer biology. Often, the perspectives that these technologies provide result in the division of a seemingly homogeneous cohort into multiple further, carefully defined subtypes. A prime example is lung cancer. Classically, lung cancer was subdivided into small cell and nonsmall cell types based on histologic appearance. Subsequently, nonsmall cell lung cancer was further divided into distinct histologic subtypes, including adenocarcinoma, squamous, and large cell, although treatment with cisplatin-based doublets was long held as the standard of care for all of them. 1 Adenocarcinoma of the lung is now further subdivided based on the presence or absence of driver mutations. Given the development of potent inhibitors targeting the protein products of these driver mutations, these molecularly defined subtypes of adenocarcinoma now split the disease along mutation lines to guide therapeutic decisions. For example, tumors harboring epidermal growth factor receptor (EGFR) mutations are particularly sensitive to EGFR inhibitors like erlotinib. 2 Thus, the technology-driven subtyping or "splitting" of cancers has directly impacted treatment paradigms.
The EGFR lung adenocarcinoma breakthrough is but one of several such examples in oncology in which the molecular features of a patient's tumor directly dictates therapeutic decisions. The success of these select examples, coupled with the momentum stemming from advanced technologies in molecular biology, has fueled enthusiasm for precision medicine. Precision, also referred to as personalized, cancer medicine, as defined by the National Cancer Institute, is the use of specific information about a patient's tumor to aid in diagnosis, planning treatment, assessing the effects of treatment, and prognostication. To date, if cancer care is to pursue this model of medicine, then a path can be envisioned toward further and further "splitting" of tumors. In fact, an extreme interpretation of personalized medicine is that no 2 patients (and thus no 2 tumors) are identical. Furthermore, we now know that individual tumors are heterogeneous and constantly evolving. 3 Thus, "splitting" to the extreme will result in the identification of genomically and phenotypically distinct subregions within an individual patient's tumor.
Identifying individual tumors in individual patients and designing individualized treatment plans based on these data are exciting and appealing. However, practically, such pursuits make the development of novel therapeutics, provider education, and regulation significantly more difficult. In addition, given the finite size of the human genome, the number of ways in which a cancer cell can program itself is immense and diverse but perhaps not infinite. Thus, it is not surprising that the pursuit of "personalized cancer medicine" has witnessed examples of the pendulum swinging away from ever more subtypes or "splitting" of tumors and toward a system, in which tumors that share a certain molecular feature are "lumped" together for study purposes, including drug development. For example, it was discovered that a subgroup of esophagogastric adenocarcinoma overexpressed the receptor tyrosine kinase human endothelial receptor 2 (HER2). HER2 is also overexpressed in breast cancer, in which multiple agents that target this specific protein have been tested and proven effective. Indeed, when treated with targeted drugs, the metastatic HER2-overexpressing esophagogastric adenocarcinomas demonstrated a response. 4 Thus, in this example, HER2-overexpressing tumors can potentially be "lumped" together with the use of similar drugs. This system of "lumping" of otherwise very dissimilar tumors, in this case breast and gastric adenocarcinomas, with distinct sites of origin, epidemiology, and pathogenesis can be viewed as the antithesis to the parsing of similar tumors into further and further subdivisions. In this review, our objectives are to describe these seemingly antagonistic trends specifically in renal cell carcinoma (RCC) and to explore how these trends may impact patient care in the near future.
THE EVOLUTION OF RCC SUBCLASSIFICATION: A PATH OF "SPLITTING"

Introduction to RCC Histologic Subtypes
It is now well accepted across the RCC community that kidney tumors that look very different when examined under magnification are distinct diseases with divergent biology. This simple conclusion, which may seem selfevident to the modern physician and investigator, actually took decades of analysis and the molecular biology revolution to become realized. For decades, most or all kidney tumors were lumped under a single title. 5 Although other early pathologists described kidney tumors with papillary features, 6 not until the 1970s was "papillary" RCC studied in a detailed manner with clinical and pathologic correlation. 7 These and other studies marked a transition in which investigators began to increasingly appreciate and describe distinct histologic subtypes of kidney cancer. Thus, what were once collectively known as "hypernephromas" would eventually be "split" into at least 16 distinct subtypes through the application of various histologic and molecular criteria (Table 1) . [8] [9] [10] [11] [12] Enthusiasm for this system of splitting RCC into many subtypes was fueled by recognition that core biology, clinical features, and even response to treatments can be very different among the subtypes.
Histologic Subtypes of RCC
Clear cell RCC
The most common histologic subtype of RCC is the clear cell variant, representing from 70% to 75% of adult RCCs. These tumors tend to be vascular and can have macroscopic evidence of hemorrhage and necrosis, as astutely described by early pathologists. 5 Microscopically, these tumors are characterized by clear cytoplasm because of an abundant accumulation of glycogen and lipids. 14 One copy is either mutated or silenced in up to 90% of sporadic clear cell RCC tumors, 15 whereas the second copy is typically lost through chromosome 3p deletions. 16 Under physiologic and normoxic conditions, the VHL protein is an important component of an E3 ubiquitin ligase complex that targets the hypoxia-inducible factors (HIFs) for proteasome-mediated degradation. However, biallelic loss of VHL allows for the inappropriate stabilization of HIFs (irrespective of oxygen levels), which results in a proangiogenic gene expression signature critical to clear cell RCC tumorigenesis. 17 This "pseudohypoxic" response has come to define clear cell RCC biology and distinguishes it from other RCC histologies.
Papillary RCC
Papillary RCC is the second most common histologic subtype of adult kidney cancer, representing about 15% of cases. This variant of kidney cancer with papillary or tubulopapillary architecture was recognized early, as discussed above. 6 However, its recognition as a distinct subtype of kidney cancer gained traction, because it was recognized that these tumors had a distinct clinical course 7 and molecular features relative to the more common clear cell variant. Specifically, although 3p loss is nearly universal in clear cell RCC, early kidney cancer cytogenetic studies demonstrated that this chromosomal abnormality was absent in most papillary RCCs, 18 thus further supporting the concept that papillary RCC was biologically and clinically distinct from clear cell RCC.
Later, as larger papillary RCC cohorts were studied, it became evident that this disease could be further subdivided on the basis of histology into 2 subtypes. Type 1 papillary RCC was characterized by papillary or tubular structures covered by small, basophilic cells with clear cytoplasm that have small nuclei and inconspicuous nucleoli; whereas type 2 papillary RCC was characterized by larger cells with eosinophilic cytoplasm, pseudostratification of cells, and prominent nucleoli. 19 Moreover, familial studies reveal that germline mutations contribute specifically to inherited forms of both disease types-hereditary papillary renal carcinoma syndrome with germline mutations in MET protooncogene, (MET), giving rise to type 1 tumors, 20, 21 and hereditary leiomyomatosis and RCC syndrome with germline mutations in fumarate hydratase, giving rise to type 2 tumors. Large genomic studies have demonstrated strong molecular distinctions between sporadic papillary type 1 and type 2 RCC. Type 1 disease is characterized by molecular events that result in amplification of signaling from the hepatocyte growth factor receptor MET, most commonly gain-of-function somatic mutations in the tyrosine kinase domain 22 ; whereas type 2 disease itself is more heterogeneous, with loss of cyclin-dependent kinase 2a (CDKN2a) function, activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) antioxidant response element pathway, and mutations in chromatin regulators, 22 allowing the type 2 papillary tumors to be further subdivided into at least 3 additional subclassifications.
Thus, type 1 and 2 papillary RCCs have become fully recognized not only as distinct from clear cell RCC but also as distinct from each other.
Other histologic subtypes of RCC
Although clear cell and papillary RCC are the 2 most common subtypes of kidney cancer, representing 80% to 90% of cases, others have been described with increasingly robust molecular annotation. Chromophobe RCC represents approximately 5% of adult kidney cancer and microscopically features distinct cell borders and voluminous cytoplasm. 13 Two histologic subtypes have been described even for this rare tumor entity: classic and eosinophilic. Classic chromophobe has a pale cytoplasm and is more likely to demonstrate the characteristic monosomy chromosomal pattern often associated with chromophobe RCC, which includes loss of most or all of an entire copy of chromosome 1, 2, 6, 10, 13, 17, and often chromosome 21. 23 In addition, the classic chromophobe subtype contains more somatic mutations, including mutations in tumor protein 53 (TP53) and phosphatase and tensin homolog (PTEN). In addition, the eosinophilic subtype has dense, pink cytoplasm because of mitochondrial accumulation. It is noteworthy that the eosinophilic subtype is enriched with mutations in mitochondrial genes, specifically those corresponding to complex 1 of the electron transport chain. 23 Therefore, like other RCC histologies, it has been demonstrated that variants of chromophobe RCC have distinct molecular features, thus justifying their classification as distinct cancers. To extend the splitters mindset, each of these subtypes can be further affected by the involvement of sarcomatoid histology. So-called sarcomatoid tumors sometimes have such overwhelming sarcomatoid features that the underlying primary tumor type is unidentifiable. Recent genetic analysis has demonstrated that a common profile of mutations can contribute to this aggressive histology, 24 and combination chemotherapy regimens incorporating targeted therapies can be used for this splinter group. 25 Clear cell, papillary, and chromophobe RCCs have a commonality, in that it is believed that they all originate in the renal cortex: clear cell and papillary RCCs originate in the proximal convoluted tubule, and chromophobe RCCs originate in the distal convoluted tubule. 16, 22, 23 In contrast, other kidney tumors originate outside the renal cortex and include collecting duct (or Bellini tumors) and medullary carcinomas. Both are thought to arise from the renal medulla. Relatively less is known about these rare kidney cancer subtypes. Collecting duct carcinomas were recognized as a distinct clinical diagnosis in the 1980s and are characterized by a tubulopapillary pattern and desmoplastic stroma 26 ; in some cases, they are difficult to distinguish histologically from urothelial carcinomas. However, biologically, they may be very different from urothelial carcinomas, because the 2 cancers contain very different patterns of chromosomal gain and loss. 27 Medullary carcinomas most commonly arise in young patients with sickle cell trait. 28, 29 Even less is known about their molecular biology, although mutations in SMARCB1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1) appear to dominate their genetic profile, 30 rendering them further distinct from the other histologic subtypes described.
Clinical significance of histologic subtypes of RCC
Although it is clear that several histologic subtypes exist within the RCC spectrum, and detailed molecular studies have shed light on their divergent biology, enthusiasm for "splitting" this disease has been fueled by the clinical relevance of the subtypes. Specifically, the histologic subtypes can vary greatly in terms of prognosis. For example, initially, it seemed that papillary RCC had a favorable prognosis relative to clear cell RCC. 7 However, with the emergence of histologic papillary RCC subtypes, the story became more complicated. It is now clear that patients with MET-driven, papillary RCC type 1 tumors have a favorable prognosis, and most represent early stage disease; whereas patients with papillary RCC type 2 tumors have a high rate of metastasis and poor overall survival. 22 Distal tubule-derived, chromophobe RCCs rarely metastasize, and patients do well, whereas tumors that arise from the renal medulla (namely, collecting duct and medullary carcinomas) represent extremely aggressive disease with a poor overall prognosis. In 1 series of renal medullary carcinoma, the mean survival was a mere 4 months. 29 Thus, precise histologic subclassification can provide a profound contribution to the understanding of an individual patient's prognosis.
The clinical relevance of RCC histologic subtypes informs not only prognosis but, in some instances, can guide treatment decisions. For example, in the early studies of immunotherapy in RCC using high-dose interleukin-2, researchers observed that the response rate was superior for patients with clear cell RCC relative to those with nonclear cell RCC subtypes for reasons that remain poorly understood. 31 Those observations also have been validated in more recent prospective analyses. 32 However, the development of a new class of medications would cause a dramatic shift in the design of prospective RCC trials. The molecular hallmark of clear cell RCC (but not of other subtypes), as discussed above, is biallelic loss of VHL with resultant HIF stabilization and inappropriate hypoxia signaling, including profound increases in angiogenesis signaling. 17 This signaling includes increased production of vascular epithelial growth factor (VEGF) and subsequent signaling through the VEGF receptors (VEGFRs), a class of receptor tyrosine kinases. Signaling through the VEGFRs, especially on endothelial cells, supports the tumor vasculature and growth. When a novel class of small-molecule inhibitors was designed to target VEGFRs, the large phase 3 trials typically included a "clear cell component" as an inclusion criterion for describing the histology. 33, 34 Those trials established the VEGFR inhibitors as the new standard first-line therapy for metastatic clear cell RCC. The exclusion of nonclear cell RCC was justified, because it was predicted that these patients with VHL-intact disease would not obtain as much benefit from this class of drugs. Thus, for some time, it was unclear whether patients with nonclear cell RCC benefited from VEGFR inhibitors. Attempts to design VEGFR inhibitors with an increased target spectrum tailored to papillary RCC biology has had mixed results. Specifically, foretinib has activity against both MET and VEGFR and was tested in a phase 2 trial for patients with papillary RCC. 35 Although foretinib did have activity, the most robust responses were observed in patients who had germline MET mutations (ie, most likely a small subset of those with papillary type 1 tumors). However, novel combinations like bevacizumab and erlotinib, which target angiogenesis and glucose transport, respectively, in the highly glycolytic fumarate hydratase (FH)-mutant papillary type 2 group, are being carefully examined. 36 Thus, in the antiangiogenesis era, "splitting" RCC on the basis of histology has had a dramatic impact on clinical trial design.
Molecular Subtypes of RCC
Given the importance of histologic subclassification in prognosis and therapy, investigators have been aggressive in identifying molecular subtypes in an attempt to build on this success. Although some other nonclear cell RCC histologic subtypes, such as papillary and chromophobe RCC, can be further subdivided based on histology, clear cell RCC is relatively homogenous. Because clear cell RCC represents the largest bulk of patient burden, there has been great interest in identifying molecular subtypes that can further inform prognosis, biology, and drug development. One such example emerged when investigators examined patterns of HIF staining in 160 sporadic human clear cell RCC tumors and split the tumors into 3 groups: VHL wild-type, tumors that were positive for both HIF-1a and HIF-2a (H1H2), and tumors that were positive only for HIF-2a (H2). 37 The H1H2 tumors exhibited increased angiogenesis as well as increased protein kinase B/mammalian target of rapamycin (AKT/ mTOR) and mitogen-activated protein kinase 1 (ERK/ MAPK1) signaling, whereas the H2 tumors demonstrated increased c-Myc activity and enhanced proliferation, features that could impact therapy effectiveness but remain untested.
An alternative strategy for splitting clear cell RCC was developed from gene expression data. By using genome-wide messenger RNA microarray data, unsupervised clustering identified 2 dominant clear cell RCC subtypes called ccA and ccB. 38 Biologically, these subtypes are distinct: ccA tumors exhibit increased angiogenesis, whereas ccB tumors demonstrate increased transforming growth factor b (TGF-b) and epithelial-to-mesenchymal signaling. Perhaps most important, this classification represents clinically distinct subtypes, with ccB tumors demonstrating increased tumor size, grade, and rate of metastasis as well as decreased recurrence-free and overall survival in multiple data sets. 16, 39, 40 In addition, these molecular subtypes feature distinct metabolic patterns, with the aggressive ccB tumors demonstrating increased glucose uptake on imaging. 41 However, the other clear finding from that study was that individual tumors can harbor both ccA and ccB components, making this classification strategy difficult for informing therapeutic selection, although it has emerged as a strong prognostic indicator in numerous studies. 40, 42 Other investigators have successfully merged gene expression data with metabolomics profiling to parse clear cell RCC into multiple molecular subtypes, including an aggressive cohort with increased glutathione metabolism. 43 Finally, building off the results from large-scale genome sequencing projects, another schema has emerged that focuses on 2 of the more commonly mutated genes in clear cell RCC: protein polybromo-1 (PBRM1 [also called BAP180]) and BRCA1-associated protein 1 (BAP1). 16 Both genes are involved in chromatin regulation, and mutations in these genes are typically mutually exclusive. By using immunohistochemistry assays that evaluate protein expression and are known to reliably correlate with mutation status, large clinically annotated tissue microarrays were used to segregate clear cell RCC tumors into 1 of 4 categories: tumors that express both PBRM1 and BAP1 (40%), BAP1-positive tumors (49%), PBRM1-positive tumors (9%), and tumors that are negative for both proteins (2%). 44 The best prognosis was in the group that expressed both PBRM1 and BAP1 (and thus was expected to lack mutations in these genes), whereas the worst prognosis was associated with the group that lacked expression of both proteins (and thus were expected to be doubly mutated). Therefore, by using several powerful molecular platforms, various schemas to identify prognostically significant molecular subtypes of clear cell RCC have emerged, possibly indicating a future in which we can deliver personalized therapy based on these features.
Until recently, molecular subtyping of nonclear cell RCC tumors was relatively unexplored. However, the Cancer Genome Atlas working group has used multiple platforms to molecularly annotate papillary RCC. 22 Their integrated analysis identified 4 major molecular subtypes of papillary RCC. One subtype included predominantly papillary RCC type 1 tumors that frequently exhibit MET activation, whereas the other 3 subtypes included mostly papillary RCC type 2 tumors, thus reflecting the molecular heterogeneity of this subtype. Among these 3 molecular subtypes of papillary RCC type 2 tumors, 1 was notable for its extremely poor prognosis and young age of onset. Termed CpG island methylator phenotype or CIMP, these tumors were identified by their widespread pattern of genomic hypermethylation. They also frequently had CDKN2a silencing and included all tumors with FH germline mutations, a uniquely aggressive subgroup originally identified through the association with the familial syndrome of hereditary leiomyomatosis Review Article and Renal Cell Cancer (HLRCC). 45 Thus, although papillary type 1 RCC was relatively homogeneous, papillary type 2 RCC displayed far more molecular heterogeneity, and multiple molecular subtypes were identified.
THE CASE FOR LUMPING
Although it is relatively simpler (in the mind of an avowed splitter) to apply definitions with greater and greater specificity, a strong rational case can be made for lumping strategies, particularly given the strong reinforcement that has come from decades of trials that effectively lump all of the RCCs together. This strategy simplifies enrollment in studies and provides treatment options for a greater range of patients. Although the nonclear cell histologies always make up a tiny minority of cases, clinical trials have not consistently demonstrated inferiority for this practice. 46 Moreover, despite the extensive subclassification strategies available, histologically, it is still not uncommon for tumors to be assigned a diagnosis of "unclassified" RCC or "renal epithelial tumor not otherwise specified." This is because of the wide variation in histologic features even within subtypes and a current lack of effective molecular tools to augment pathologic assignment. Indeed, studies demonstrate the activity of standard frontline VEGFR-targeted therapies in papillary RCC 47 and even in chromophobe RCC. 48 Even including the sarcomatoid variant classification, data suggesting that VEGFR-targeted therapies can be effective 49 reinforce the lumping paradigm. In addition, because these various histologies are treated with similar therapies, it is possible that convergent resistance mechanisms could emerge that likewise could be treated similarly.
The same was true for some early pivotal trials with another class of medications: the mTOR inhibitors. Specifically, in a first-line trial comparing the mTOR inhibitor temsirolimus versus interferon-a or the combination in patients with metastatic RCC, nearly 20% of enrollees had nonclear cell RCC histologies. 50 That trial was limited to patients who had poor-prognosis disease, as defined by clinical criteria. 51 Because temsirolimus proved to be superior to interferon-a and equivalent to the combination, it has emerged as an accepted therapy for patients who have poor-risk primary RCC regardless of histologic subtype.
Although many of the studies described above have focused primarily on defining disease biology without much consideration to therapeutics, in fact, the biologic underpinnings can make the case strongly in favor of lumping-as in lumping tumors according to biologic properties. For example, investigators identified 5 patients with RCC who had an "exceptional" response to mTOR inhibitors (median duration of response, 28 months). 52 One of those patients had an RCC that could not be histologically subtyped, whereas the other 4 had RCCs with clear cell histology. Multiple specimens were obtained from each patient, and genomic sequencing was performed. It is noteworthy that nearly all of the samples identified activating alterations of the mTOR pathway. Therefore, the use of genomic sequencing to identify a subgroup of patients who are more likely to respond to mTOR inhibitors is an exciting approach to RCC therapeutics. This strategy is becoming increasingly popular, and the use of basket-style trials supports even broader lumping of disease types according to underlying genomic analysis rather than according to tissue of origin. 53 Previously, the defining biologic features of the major subtypes of RCC were highly distinct, as detailed above, which warranted the strong concern against lumping strategies. However, recent high-throughput sequencing efforts have revealed new themes of somatic alterations that cross histologic boundaries. In addition to inactivating mutations in PTEN and related members of the tuberous sclerosis complex (TSC)/mTOR signaling axis, mutations in chromatin modifiers, such as SET domain containing 2 (SETD2) and PBRM1/BAF180, are also prevalent across the RCC spectrum. 16, 22, 23 Thus, as new therapeutics emerge that target cells that have specific somatic dependencies, the options to lump tumors according to precision genomic strategies will only increase.
For better or worse, the newest therapies in this disease rely on targets for which we have very little knowledge to guide their use. The immunotherapies-formerly dominated by high-dose interleukin-2, which was widely accepted to be exclusively active in clear cell RCC as well as melanoma-are now rapidly changing form with the advent of programmed death 1 (PD-1)-inhibitory, PD-1 ligand (PD-L1)-inhibitory, and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4)-inhibitory antibodies. These therapies hold great promise for deep, sustainable responses in a surprisingly broad array of tumor types. The pivotal, positive phase 3 trial of nivolumab versus everolimus in previously treated patients that resulted in the approval of nivolumab was limited to patients who had clear cell RCC, 54 although the indication was delivered broadly to patients who had advanced, previously treated RCC. In fact, it has been demonstrated that PD-L1 is expressed on both clear cell and nonclear cell RCC tumors. 55, 56 Despite this observation, many ongoing Figure 1 . Representation of the 2 schools of thought. Top: Splitting demonstrates the narrower definitions obtained by applying increasingly strict criteria. Possible treatment strategies for subtypes are listed. Bottom: Lumping combines groups according to similar features or, in this example, according to therapies that have demonstrated benefit to the group. *Although programmed death ligand 1 (PD-L1) staining has been observed in both clear cell and nonclear cell renal cell carcinoma (RCC), the activity of checkpoint inhibitors in nonclear cell RCC has not been well studied. However, PD-L1 staining is an important example of how biomarkers for specific classes of drugs can cross over previously defined "splitting" schemas. BAP1 indicates BRCA1-associated protein 1; ccA/ccB, dominant clear cell RCC subtypes; CD, collecting duct; CIMP, CpG island methylator phenotype; DCT, distal convoluted tubule; H1, hypoxia-inducible factor 1a; H2, hypoxia-inducible factor 2a; mTOR, mammalian target of rapamycin; PCT, proximal convoluted tubule; PRBM1, protein polybromo-1; anti-VEGF, antivascular endothelial growth factor.
prospective trials, including those using check-point inhibitors, are following the pattern from the antiangiogenesis era and limiting inclusion to those patients whose tumors contain a clear cell component (eg, national clinical trials NCT01472081 and NCT02575222). Thus, we may need to wait for retrospective analyses of off-study patients or novel trial designs to address the question of the impact of histology on patient outcomes with checkpoint inhibitors. For now, however, many tumors are finding themselves lumped together as we search for clues to understand the arbiters of response to this new class of immune therapies.
Conclusion
RCC is no longer recognized as a single disease but, rather, as a collection of related, yet biologically distinct, cancers. Through the use of detailed molecular studies, we know that these histologically divergent tumors are also biologically divergent, with unique mutational burdens, gene expression patterns, proteomic profiles, and metabolomic signatures. Even among populations with histologically indistinguishable tumors, molecular profiling has allowed us to parse out biologically unique subtypes. These molecular subtypes are clinically relevant, as evidenced by their dissimilar recurrence and survival rates. This work has led to new knowledge and insight into the core biology of these tumors that is unparalleled in the history of the disease (Fig. 1) . Although our understanding of the biologic subtypes of RCC has progressed relatively quickly, the pace of clinical discovery to meet these diseases with precision approaches has lagged. There are several possible explanations why the identification of more and more molecularly distinct subtypes of RCC has not always resulted in immediate clinical advances. First, a lack of effective therapies is an obvious hindrance to improving RCC care. Regardless of how many times RCC is "split" into biologically defined subtypes, if all subtypes are resistant to available therapies, then little clinical progress can be made. By the same token, if targeted therapies lack specificity for driver events, as in the case of the VEGFRtargeted therapies, which target the tumor vasculature, then it is not surprising that these treatments can have broad activities in various tumor types. Thus, we have yet to develop a highly potent and durable, targeted therapeutic paradigm that exploits the deviant biology of the renal tumor subtypes. These precise tools are on the horizon, and it will be in our best interest as a community to be ready to integrate such new drugs with accurate classification schemes and annotation strategies for RCCs.
Although a detailed understanding of RCC biologic subtypes has undoubtedly led to a deeper understanding of the diverse biology within this disease spectrum, and the development of matched therapies that target the driver biology is arguably the best approach to obtaining the ideals of precision medicine, difficulties ascertaining this ideal should not paralyze drug development. For example, the checkpoint inhibitors represent an exciting, novel therapeutic approach in RCC. This method of escaping immune surveillance, including expression of PD-L1, is used by many RCC subtypes, as mentioned above. Thus, as more is learned about this biology across the RCC spectrum, new "splitting" paradigms likely will emerge that incorporate this important biology with what has been previously described. However, currently, it is practical and even essential that we "lump" tumors together based on this biology for purposes of biomarker development and clinical trial design. 
